The Relationship Between Panic Attack Symptoms and Atrial Fibrillation Episodes.
Megadott ok: Unable to enroll the required number of subjects to achieve statistically significant results. There were no adverse events to report.
Key facts
- Where
- Buffalo, Egyesült ÁllamokSee the site
Where in Egyesült Államok
- University at BuffaloBuffalo, Egyesült ÁllamokNo longer taking part
Trial details
- Who runs it
- State University of New York at Buffalo
- Trial code
- NCT04634461
- Record updated
- 2025. április 13.
- Original description
To characterize the relationship between panic attack symptoms and atrial fibrillation episodes using a real-time assessment data capturing system that reduces recall biases of previous research.Read full original descriptionShow less
To characterize the relationship between panic attack symptoms and atrial fibrillation episodes using a real-time assessment data capturing system that reduces recall biases of previous research.
Inclusion: Patients (male and female) between 21 - 75 years of age; Patients of both sexes, of varying races and ethnicities, with a range of educational levels and ages; ICD-10 diagnosis code of PAF in the electronic medical record or ECG demonstrating PAF in the chart; History of PA symptoms as identified on screening with the PHQ-PD; Read and speak English; Access to a smartphone and internet/data coverage; Ability to read and type within a smartphone-based application; Capacity to understand and provide informed consent, and comply with protocol requirements that includes completion of a limited number of questionnaires.
Exclusion: Patients on rhythm control medications and expected to have changing dose during the study (not excluded if patient anticipated to be on stable dose throughout duration of the study: 30 days); Uncontrolled hypertension (defined as documented BP readings consistently above 140/90); Reversible causes of AF, which include but are not limited to untreated thyroid disease, recent major surgical procedure or trauma, etc; History of persistent or chronic AF; History of clinically significant valvular heart disease (bio prosthetic or mechanical valve, severe aortic stenosis, moderate to severe mitral stenosis, rheumatic heart disease, or severe mitral regurgitation); History of new onset coronary artery disease (CAD) in the last 90 days; History of myocardial infarction (MI) in the last 90 days; History of percutaneous coronary intervention in the last 90 days; History of coronary artery bypass grafting in the last 90 days; History of untreated obstructive sleep apnea (OSA); History of severe pulmonary hypertension; History of cerebrovascular injury (stroke, transient ischemic attack, traumatic brain injury) in the last 90 days; Dementia or any form of cognitive impairment that precludes the patient from providing consent; Patients with a major psychiatric disorder which, in the opinion of the investigator, may impede his/her participation in the study. These disorders include, but are not limited to, major depression with high likelihood of suicidal behavior (i.e., intent or plan), alcohol or substance abuse/dependence within the past year, lifetime history of schizophrenia or schizoaffective disorder, psychoses, mania; History of congestive heart failure (CHF) and an ejection fraction (EF) of less than 40%; Patients younger than 21 years old or older than 75 years old; Morbid obesity, Body Mass Index (BMI) >40 kg/m2; Pregnant women; Patients who do not have a smartphone device; Uncompensated hearing or visual defects; Patients unable to communicate verbally in English; Patients who are unable to fully comprehend the consent forms; Medically unstable patients or patients who have a life expectancy less than the anticipated duration of the study.